110 recruiting, 72 not yet recruiting, 50 completed, 18 active not recruiting. 89 Phase 2, 46 Phase 1, 42 Not applicable, 19 Phase 3, 6 Early Phase 1.
Follow Hepatocellular Carcinoma (HCC): new trials by email Literature Review of Hepatocellular Carcinoma (HCC) trials Research Report on Hepatocellular Carcinoma (HCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. TheraSphere - Hepatocellular Carcinoma (HCC) | Not yet recruiting | Boston Scientific Corporation | 140 | 2027-01-01 | 2026-10-01 | |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review - Hepatocellular Carcinoma (HCC), Liver Cancer, Adult | Phase 2 | Not yet recruiting | University of California, San Francisco | 50 | 2026-12-15 | 2026-10-13 |
| Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma Zanzalintinib, Tegavivint - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 36 | 2026-12-01 | 2026-10-16 |
| Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer Lenvatinib, Tislelizumab, Gefitinib - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 120 | 2026-11-01 | 2026-09-21 |
| Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs ACE723 - Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic | Phase 1 | Not yet recruiting | Acepodia Biotech, Inc. | 70 | 2026-11-01 | 2026-10-06 |
| STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma (HCC) | Recruiting | Universitaire Ziekenhuizen KU Leuven | 280 | 2026-10-15 | 2026-10-07 | |
| SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 33 | 2026-10-15 | 2026-10-20 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma No investigational intervention. Participants receive standard clinical care. Clinical data, imaging/pathology information, and available biospecimens are collected for research. - Hepatocellular Carcinoma (HCC) | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 500 | 2026-10-12 | 2026-09-24 | |
| Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical Microwave Ablation Assisted by Diaphragm Hydrodissection, Surgical Resection - Hepatocellular Carcinoma (HCC) | Not yet recruiting | The First Hospital of Jilin University | 200 | 2026-10-01 | 2026-09-11 | |
| A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis. SIR-Spheres Selectively Delivered to Liver Tumor - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Sirtex Medical | 78 | 2026-10-01 | 2026-06-25 |
| Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for Subcapsular Hepatocellular Carcinoma No-touch Microwave Ablation, Tumor-puncture Microwave Ablation, Surgical Resection - Hepatocellular Carcinoma (HCC) | Not yet recruiting | The First Hospital of Jilin University | 180 | 2026-10-01 | 2026-08-05 | |
| AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation Artificial Intelligence-Guided Risk-Adapted Surveillance, Fixed-Interval Surveillance - Hepatocellular Carcinoma (HCC) | Not applicable | Not yet recruiting | Tongji Hospital | 2000 | 2026-10-01 | 2026-07-29 |
| TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602) Hepatocellular Carcinoma (HCC) | Not yet recruiting | Zhongda Hospital | 596 | 2026-09-30 | 2026-09-23 | |
| Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tocilizumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | CHA University | 51 | 2026-09-01 | 2026-08-19 |
| A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma) Colorectal Cancer (CRC), Gastric Cancer (GC) | Recruiting | Jie Yuan，MD | 30 | 2026-09-01 | 2026-09-30 | |
| GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma 18F-X12 PET/CT - Hepatocellular Carcinoma (HCC) | Not applicable | Recruiting | Peking University First Hospital | 100 | 2026-08-25 | 2026-09-02 |
| Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Nivolumab, Ipilimumab (3 mg/kg) - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-08-21 | 2026-08-25 |
| HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B No intervention (observational study) - Hepatocellular Carcinoma (HCC) | Not yet recruiting | Beijing Friendship Hospital | 2000 | 2026-08-20 | 2026-08-28 |
Showing 20 of 279. Sign in to see all of them.
Carcinoma, Hepatocellular (279) · Liver Neoplasms (19) · Cholangiocarcinoma (15) · Carcinoma, Renal Cell (12) · Colorectal Neoplasms (11) · Liver Cirrhosis (8) · Melanoma (8) · Neoplasm Metastasis (8) · Carcinoma, Non-Small-Cell Lung (7) · Recurrence (7) · Stomach Neoplasms (7) · Endometrial Neoplasms (6) · Neoplasms (6) · Ovarian Neoplasms (6) · Fibrosis (5)
Adenocarcinoma (279) · Digestive System Diseases (279) · Digestive System Neoplasms (279) · Neoplasms by Histologic Type (279) · Neoplasms by Site (279) · Neoplasms, Glandular and Epithelial (279) · Carcinoma (278) · Liver Diseases (276) · Neoplasms (273) · Liver Neoplasms (260) · Pathological Conditions, Signs and Symptoms (35) · Pathologic Processes (32) · Gastrointestinal Diseases (20) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19)
Bevacizumab (17) · lenvatinib (13) · Nivolumab (10) · atezolizumab (9) · sintilimab (9) · Radiosurgery (8) · Ipilimumab (7) · Sorafenib (7) · tislelizumab (7) · durvalumab (5) · regorafenib (5) · Observation (4) · Blood Specimen Collection (3) · Immune Checkpoint Inhibitors (3) · Immunotherapy (3)
Sun Yat-sen University (9) · Tongji Hospital (9) · Seoul National University Hospital (6) · Shanghai Zhongshan Hospital (6) · Anhui Provincial Hospital (5) · First Affiliated Hospital, Sun Yat-Sen University (5) · Fudan University (5) · Nanfang Hospital, Southern Medical University (5) · National Taiwan University Hospital (4) · The First Hospital of Jilin University (4) · Zhongda Hospital (4) · Ain Shams University (3) · Assiut University (3) · Beijing Gene Key Life Technology Co., Ltd (3) · Incyte Corporation (3)
China (136) · United States (43) · South Korea (20) · Taiwan (19) · France (18) · Germany (15) · Italy (14) · United Kingdom (12) · Spain (9) · Canada (8) · Belgium (7) · Australia (6) · Hong Kong (6) · Japan (6) · Singapore (6)
Jian Zhou (3) · David Hsieh, MD (2) · Dou-sheng Bai (2) · Gao-jun Teng, M.D (2) · Meng Liu (2) · Salah-Eddin Al-Batran, Prof. Dr. (2) · Yan Sun, MD (2) · Ze-yang Ding, M.D. (2) · Achim Kautz (1) · Adrian Radu Vidra (1) · Ahmed Helmy Salem, professor (1) · Ajay Goel, PhD (1)
PMID 31439937, PMID 32402160, PMID 34143971, PMID 37796513, PMID 10636774, PMID 19058754, PMID 19212170, PMID 21349999, PMID 25614940, PMID 26135698, PMID 26470869, PMID 27816492, PMID 28187290, PMID 28371798, PMID 28420329, PMID 28886381, PMID 29307467, PMID 29433850, PMID 29437535, PMID 29653628, PMID 29802174, PMID 29875066, PMID 30207593, PMID 30449599, PMID 30969136, PMID 30970190, PMID 31080879, PMID 31219706, PMID 31249394, PMID 31287387, PMID 31428580, PMID 31720835, PMID 32265508, PMID 32333081, PMID 32569799, PMID 32716739, PMID 32998878, PMID 33001135, PMID 33028595, PMID 33412628, PMID 33538338, PMID 33945007, PMID 33948712, PMID 34051880, PMID 34087115, PMID 34122737, PMID 34136141, PMID 34648352, PMID 34905388, PMID 35065058
2017 (3), 2023 (2), 2014 (1), 2015 (1), 2025 (1), I01CX002654 (1), R01CA218187 (1), R01CA249765 (1), R44CA287803 (1)